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Blood-brain barrier-associated pericytes
internalize and clear aggregated amyloid-
β42 by LRP1-dependent apolipoprotein E
isoform-specific mechanism
Qingyi Ma1,2†, Zhen Zhao1†, Abhay P Sagare1†, Yingxi Wu1, Min Wang1, Nelly Chuqui Owens1, Philip B Verghese3,
Joachim Herz4,5,6, David M Holtzman7 and Berislav V Zlokovic1*
Abstract
Background: Clearance at the blood-brain barrier (BBB) plays an important role in removal of Alzheimer’s amyloid-β (Aβ)
toxin from brain both in humans and animal models. Apolipoprotein E (apoE), the major genetic risk factor for AD, disrupts
Aβ clearance at the BBB. The cellular and molecular mechanisms, however, still remain unclear, particularly whether the BBB-
associated brain capillary pericytes can contribute to removal of aggregated Aβ from brain capillaries, and whether removal
of Aβ aggregates by pericytes requires apoE, and if so, is Aβ clearance on pericytes apoE isoform-specific.
Methods: We performed immunostaining for Aβ and pericyte biomarkers on brain capillaries (< 6 μm in diameter) on tissue
sections derived from AD patients and age-matched controls, and APPSwe/0 mice and littermate controls. Human Cy3-Aβ42
uptake by pericytes was studied on freshly isolated brain slices from control mice, pericyte LRP1-deficient mice (Lrplox/lox;
Cspg4-Cre) and littermate controls. Clearance of aggregated Aβ42 by mouse pericytes was studied on multi-spot glass slides
under different experimental conditions including pharmacologic and/or genetic inhibition of the low density lipoprotein
receptor related protein 1 (LRP1), an apoE receptor, and/or silencing mouse endogenous Apoe in the presence and absence
of human astrocyte-derived lipidated apoE3 or apoE4. Student’s t-test and one-way ANOVA followed by Bonferroni's post-
hoc test were used for statistical analysis.
Results: First, we found that 35% and 60% of brain capillary pericytes accumulate Aβ in AD patients and 8.5-month-old
APPSw/0 mice, respectively, compared to negligible uptake in controls. Cy3-Aβ42 species were abundantly taken up by
pericytes on cultured mouse brain slices via LRP1, as shown by both pharmacologic and genetic inhibition of LRP1 in
pericytes. Mouse pericytes vigorously cleared aggregated Cy3-Aβ42 from multi-spot glass slides via LRP1, which was
inhibited by pharmacologic and/or genetic knockdown of mouse endogenous apoE. Human astrocyte-derived
lipidated apoE3, but not apoE4, normalized Aβ42 clearance by mouse pericytes with silenced mouse apoE.
Conclusions: Our data suggest that BBB-associated pericytes clear Aβ aggregates via an LRP1/apoE isoform-specific
mechanism. These data support the role of LRP1/apoE interactions on pericytes as a potential therapeutic target for
controlling Aβ clearance in AD.
Keywords: Pericyte, Blood-brain barrier (BBB), Amyloid-β clearance, Low-density lipoprotein receptor-related protein 1
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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder associated with cognitive impairment, early
neurovascular changes, accumulation of amyloid-β (Aβ)
and tau pathology, and neuron loss [1, 2]. According to the
amyloid hypothesis, the build-up of Aβ in the brain paren-
chyma [3–5] and blood vessels [6–9] is the key event lead-
ing to other AD-related pathologies and disease symptoms.
In the brain, Aβ is produced by neurons and other cell
types, and is constantly removed by several clearance
mechanisms. This includes receptor-mediated transport
across the blood-brain barrier (BBB) into the peripheral
circulation [10], enzyme-mediated Aβ proteolytic degrad-
ation [11], removal by glial cells [12], and diffusive trans-
port across the interstitial fluid (ISF) along the perivascular
spaces [13–15] leading to drainage by the meningeal
lymphatic system [16, 17]. The imbalances between Aβ
production and clearance result in Aβ deposition in the
brain [18]. Kinetic studies in patients diagnosed with spor-
adic AD indicate that faulty Aβ clearance, rather than Aβ
overproduction, is critical for accumulation of Aβ in the
brain [19]. Moreover, recent transport studies in humans
have shown that up to 50% of the Aβ in the brain is trans-
ported across the BBB to blood [20], confirming prior find-
ings in animal models [21, 22].
The endothelial cells of the BBB, and the
BBB-associated mural cells - pericytes and vascular
smooth muscle cells (VSMCs), and glial cells clear Aβ,
which can lead to Aβ transport across the BBB to blood,
and/or Aβ degradation by mural cells, astrocytes and/or
microglia [10, 18]. The low-density lipoprotein
receptor-related protein 1 (LRP1), an apolipoprotein E
(apoE) receptor [23, 24], mediates internalization of sol-
uble Aβ at the abluminal side of the BBB [22, 25, 26]. This
is followed by Aβ transcytosis across the BBB that is regu-
lated by PICALM (Phosphatidylinositol Binding Clathrin
Assembly Protein) and Rab5 and Rab11 small GTPases,
ultimately leading to Aβ exocytosis across the luminal side
of the BBB and clearance into the blood [27]. Conse-
quently, endothelial-specific deletion of Lrp1 gene [28] or
deletion of Picalm gene from the endothelium [27] lead to
accelerated Aβ pathology in Aβ-precursor protein (APP)
overexpressing mice. VSMCs within the small cerebral ar-
teries also clear Aβ via LRP1 [29, 30]. Similarly, astrocytes
clear deposited Aβ via LRP1, which requires mouse en-
dogenous apoE [31].
Brain capillary pericytes are centrally positioned between
brain endothelial cells, astrocytes and neurons [32]. Besides
roles in regulating BBB permeability [33, 34] and cerebral
blood flow [35], pericytes show strong phagocytic activity
associated with clearance of toxic foreign molecules [32],
and endogenous proteins [36] including Alzheimer’s Aβ,
which can influence development of Aβ pathology as
shown in APP mouse models [37, 38]. Prior studies have
demonstrated that apoE disrupts Aβ clearance across the
mouse BBB [39], specifically, apoE4, which carries major
genetic risk for AD [40–42], had greater disruptive effect
than apoE3, which carries lower risk. However, the contri-
bution of BBB-associated pericytes compared to endothelial
trans-vascular transport to Aβ clearance at the BBB still re-
mains elusive, particularly, whether pericytes can contribute
to removal of aggregated Aβ from brain capillaries, which
develop cerebral amyloid angiopathy (CAA) in AD [8], and
whether removal of Aβ aggregates by pericytes requires
apoE, and if so, is Aβ clearance on pericytes apoE
isoform-specific? Here we show that Aβ accumulates in
abundance in brain pericytes in AD and APPSw/0 mice,
suggesting their active role in Aβ removal at the BBB.
Moreover, we show that pericytes internalize and clear Aβ
aggregates by an LRP1/apoE isoform-specific mechanism
implying that targeting LRP1/apoE pathway in pericytes
has potential to control Aβ clearance in AD.
Methods
Animals
Mice were housed in plastic cages on a 12 h light cycle
with ad libitum access to water and a standard laboratory
diet. All procedures were approved by the Institutional
Animal Care and Use Committee at the University of
Southern California with National Institutes of Health
guidelines. We studied APPSw/0 mice expressing human
APP transgene with the K670 M/N671 L (Swedish)
double-mutation under control of the hamster prion pro-
moter [43]. Lrplox/lox mice [44, 45] were crossed with
Cspg4-Cre mice [46] to generate Lrplox/lox;Cspg4-Cre mice
with deletions of Lrp1 gene from pericytes and oligo-
dendrocyte progenitor cells. To minimize confounding ef-
fects of background heterogeneity all experiments were
performed using age-matched littermates. Both, male and
female mice were used in the study. All animals were ran-
domized for their genotype information. All experiments
were blinded; the operators responsible for experimental
procedure and data analysis were blinded and unaware of
group allocation throughout the experiments.
Human tissue immunofluorescence analysis
Written consent was obtained and approved by the Uni-
versity of Rochester Medical Center for all studied human
subjects prior to death. The postmortem interval ranged
between 4 and 16 h. Postmortem brain tissue samples in-
cluding frontal cortex (Brodmann area 9/10) were ob-
tained from subjects with a definite diagnosis of AD
confirmed by neuropathological analysis including Braak
stages ≥ III; CERAD (Consortium to Establish a Registry
for Alzheimer’s Disease) frequent, and neurologically in-
tact controls with no AD pathology (Braak stages ≤ III;
CERAD – negative). Six controls and six AD samples were
used for the current study. Their demographic and clinical
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features were as we reported previously [47], and shown
in Additional file 1: Table S1. Vascular risk factors such as
atherosclerosis, hypertension and/or myocardial infarction
were present in 4 out 6 AD patients and 6 out of 6 con-
trols. The cause of death in all AD and control patients
was either respiratory failure or cardiac failure. All tissues
were paraformaldehyde (PFA)-fixed, paraffin-embedded
and cut to 10 μm thick slices. Sections were deparaffinized
with xylene and rehydrated to distilled water after serial
ethanol washes. Subsequently, heat-induced antigen re-
trieval (HIAR) was performed following Dako’s protocol.
The tissue sections were then blocked in 5% donkey
serum (Jackson ImmunoResearch, West Grove, PA, USA)
containing 0.3% Triton X-100 (Sigma-Aldrich, St. Louis,
MO, USA), and then incubated with the following primary
antibodies overnight at 4 °C: goat anti-human PDGFRβ
(1:100, R&D Systems, Minneapolis, MN, USA), mouse
anti-human aminopeptidase N (CD13) (1:100, R&D
Systems), rabbit anti-human Aβ (1:100, Cell signaling,
Boston, MA, USA). Blood vessels were stained by DyLight
488 Labeled Lycopersicon esculentum (Tomato) Lectin
(1:100, Vector Laboratories, Burlingame, CA, USA, #
DL-1174) for 1 h at room temperature. Species-specific
fluorochrome-conjugated secondary antibodies were incu-
bated for 1 h at room temperature, including Alexa
568-conjugated donkey anti-goat (1:200, Invitrogen),
Alexa 568-conjugated donkey anti-mouse (1:200, Invitro-
gen) and Alexa 647-conjugated donkey anti-rabbit (1:200,
Invitrogen). Tissue sections were mounted and cover-
slipped using fluorescent mounting media (Dako, Carpin-
teria, CA, USA). All slices were scanned using Zeiss 510
confocal microscopy with Zeiss Apochromat water
immersion objectives (Carl Zeiss MicroImaging Inc.,
Thornwood, NY, USA). All slices were scanned using
Zeiss 510 confocal microscopy with Zeiss Apochromat
water immersion objectives (Carl Zeiss MicroImaging
Inc., Thornwood, NY, USA), with lasers and band-pass fil-
ter settings as the following: a 488-nm argon laser to ex-
cite Alexa Fluor and Dylight 488, and the emission was
collected through a 500–550-nm bp filter; a 543 HeNe
laser to excite Alexa Fluor 568 and Cy3 and the emission
was collected through a 560–615-nm bp filter; a 633
HeNe laser to excite Alexa fluor 647 and the emission was
collected through a 650–700-nm bp filter.
Aβ uptake on freshly isolated mouse brain cortical slices
Brain slices were prepared from 2-month old C57BL6
mice or Lrplox/lox;Cspg4-Cre mice. Following the urethane
anesthesia, brains were quickly removed from the cranial
cavity and sectioned with McIlwain tissue chopper (Ted
Pella, Inc., Redding, CA, USA) into 200 μm thick slices
containing cortex and hippocampus, as previously
described [48]. Slices were recovered for 30 min in a
submersion chamber filled with the per-warmed (at 37 °C)
artificial cerebrospinal fluid (aCSF; 126 mM NaCl,
2.5 mM KCl, 1.25 mM Na2PO4, 26 mM NaHCO3, 1 mM
MgCl2, 2 mM CaCl2, 0.5 mM ascorbic acid, 2 mM sodium
pyrurate, and 10 mM glucose, saturated with 95% O2 and
5% CO2). Prior to incubation with aCSF containing 5 μg/
ml Cy3-Aβ42 for 30 min, slices were pre-incubated with
either non-immune IgG (NI-IgG) or LRP1-specific
blocking antibody [22, 29] (anti-LRP1 N20, 50 μg/ml;
Santa Cruz Biotech., Santa Cruz, CA, USA) for 20 min at
37 °C. At the end of the experiment, brain slices were
washed with phosphate buffer saline (PBS) and fixed with
4% PFA for 30 min. The same immunostaining procedure
as for human brain tissue without antigen retrieval was
performed on mouse brain slices. Primary antibodies
included goat anti-mouse aminopeptidase N (CD13)
(1:100, R&D Systems), and goat anti-mouse PDGFRβ
(1:100, R&D Systems). Secondary antibodies were: Alexa
488-conjugated donkey anti-goat (1:200, Invitrogen).
Images were obtained with Zeiss 510 confocal microscopy
(Carl Zeiss MicroImaging Inc.) with lasers and band-pass
filter settings as described above. The distribution of
Cy3-Aβ42 in pericytes and capillary endothelium was ana-
lyzed with the NIH Image J software [49].
Pericyte isolation from the mouse brain, culture and
transfection
Brain capillaries were isolated from mouse cortices pooled
from 3 to 4 mouse brains for each biological replicate. In
experiments in Figs. 4 and 5, we used 3–4 independent
biological replicates (cultures), as indicated in the legends
to these respective figures. Capillaries were isolated as we
have described previously [49, 50]. In brief, mouse cortices
were macroscopically dissected, and all visible white matter
was discarded in ice-cold PBS containing 2% fetal bovine
serum (FBS). The brain was homogenized in PBS contain-
ing 2% FBS and centrifuged at 6,000 g for 15 min after
addition of Dextran (70 kDa, Sigma). The capillary pellet
was collected and sequentially filtered through a 45 μm cell
strainer (BD Falcon). The remaining pellet on top of the
45 μm cell strainer was collected in PBS and digested for
12 h at 37 °C with collagenase A (Roche, 10103586001), as
we previously described. The cells were washed with PBS
and then plated in complete medium containing DMEM,
10% FBS, 1% non-essential amino acids, 1% vitamins and
1% antibiotic/antimycotic on plastic (non-coated) tissue
culture plates. After 6 to 12 h the non-adherent cells were
washed away and fresh medium was replaced every 2–
3 days. Cultures were confirmed to be morphological
consistent with pericyte cultures and PDGFRβ-positive,
SMA-positive, Desmin-positive, GFAP-negative, AQP4-
negative, MAP2-negative, NeuN-negative, VWF-negative,
and Iba1-negative, as previously described [37, 49]. Trans-
fections were performed with Neon transfection system
(Invitrogen, Grand Island, NY, USA) following the
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manufacturer’s protocol. After optimization, the transfec-
tion efficiency with pEGFP plasmid was > 80%. For siRNA
transfection, 15 pmol of siRNA in 1 μl was electroporated
into 1 × 105 cells in a total volume of 10 μl.
Clearance of aggregated Cy3-Aβ42 by primary mouse
brain pericytes
The multi-spot glass slides (Thermo Scientific, 9991090,
Waltham, MA, USA) were coated with Cy3- Aβ42 [29, 51]
at 1 μg per spot without cells or with brain capillary
pericytes treated with non-immune IgG (NI-IgG) or
LRP1-specific blocking antibody [22, 29] (anti-LRP1; 50 μg/
ml) or) or apoE-specific blocking antibody (anti-apoE,
HJ6.3, 50 μg/ml), scrambled siRNA (si.Control) or LRP1
siRNA (si.Lrp1) (Dharmacon, E-040764-00-0010) or apoE
siRNA (si.Apoe) (Dharmacon, E-040885-00-0005), and
500 nM receptor-associated protein (RAP) [52] (EMD
Bioscience), lipidated apoE3 (40 nM) or apoE4 (40 nM)
[49]. Cells (5,000 per spot) were incubated for 5 days in
DMEM containing 10% heat inactivated FBS, penicillin and
streptomycin (Invitrogen). Cells were labeled with Cell
Tracker Green CMFDA (Invitrogen C7025), and then fixed
with 4% paraformaldehyde. Slides were scanned using Zeiss
510 confocal microscopy (Carl Zeiss MicroImaging Inc.).
The Cy3-Aβ42 relative intensity was analyzed with the NIH
Image J software.
Purification of apoE from immortalized astrocytes
Lipidated apoE isoform particles were purified from culture
media of human apoE3 or apoE4 overexpressing immortal-
ized astrocytes using an affinity column, as we described
previously [53]. Briefly, astrocytes were cultured in ad-
vanced DMEM (Invitrogen) with 10% FBS. After 90–95%
confluency, cells were washed by PBS and further incu-
bated in advanced DMEM with N-2 Supplement (Invitro-
gen) and 3 mM 25-hydroxycholesterol (Sigma) for 3 days.
Collected culture media were applied onto mouse mono-
clonal antibody against a human apoE (WU E-4) column.
Lipidated apoE particles were eluted from the column with
3 M sodium thiocyanate, concentrated using Apollo centri-
fugal quantitative concentrators (QMWL: 150 kDa, Orbital
Biosciences), and dialyzed against PBS.
Immunoblotting
Cell samples transfected with scrambled siRNA or LRP1
siRNA were washed in cold PBS and lysed with RIPA buf-
fer. Proteins were quantified with BCA protein assay kit
(Pierce). An equal amount of protein sample was loaded
for SDS-PAGE. We used the following primary antibodies:
rabbit anti-mouse LRP1 (1: 20,000, Abcam, Cambridge,
MA, USA), β-actin (1:10,000, Sigma), and Aβ antibody
(6E10, 1:1000, Covance). Images were scanned using
ChemiDoc™ MP imager with LEDs and quantified using
Image Lab™ software (Bio-Rad, Hercules, CA, USA).
Terminal deoxynucleotidyl transferase UTP nick end
labeling (TUNEL)
Paraformaldehyde-fixed, paraffin embedded brain tissue
sections from APPSw/0 mice were sectioned at a thick-
ness of 10 μm. Immunofluorescent detection of pericytes
(CD13-positive), Aβ and endothelial-specific lectin fluor-
escence was conducted as described above. The Dead-
End Fluorometric TUNEL system (Promega) was then
completed as described by the manufacturer.
Statistical analysis
All quantified data represent as mean ± s.e.m. Student’s
t-test or one-way analysis of variance (ANOVA) followed
by Bonferroni post-hoc test was used to determine sta-
tistically significant differences. A P value < 0.05 was
considered statistically significant.
Results
Aβ accumulation in pericytes from AD patients and
APPSw/0 mice
Using 3-channel confocal microscopy, here we show that
Aβ accumulates in > 30% of CD13+ and/or PDGFRβ+ peri-
cytes on lectin+ brain endothelial capillary profiles (< 6 μm
in diameter) in brain cortical sections from AD patients
compared to barely detectable Aβ accumulation in peri-
cytes in age-matched controls (see demographic Additional
file 1: Table S1; Fig. 1a-f). To confirm this observation, we
immunostained cortical sections of 8.5-month-old APPSw/0
mice for human Aβ, at a disease stage when these mice
begin depositing Aβ [21]. We found that nearly 60% of
CD13+ pericytes were positive for human Aβ (Fig. 1g-h).
Collectively, these findings indicate that pericytes in AD
and APPSw/0 mouse brains both accumulate Aβ. Addition-
ally, we found that Aβ also accumulates in brain endothe-
lium of AD patients (Additional file 1: Figure S1A, B), and
in lectin+ brain endothelial cells of 8.5-month-old APPSw/0
mice (Additional file 1:Figure S1C).
Aβ accumulation is associated with pericyte cell death
Cultured mouse pericytes [37] and human brain pericytes
[54] die when treated with excess Aβ. To verify this result in
APPSw/0 mice in vivo, we performed quadruple TUNEL,
CD13, lectin and human Aβ staining, which revealed a sig-
nificant increase in TUNEL+ CD13+ pericytes in 8.5-month
old, but not 3-month old, APPSw/0 mice compared to
8.5-month old littermate controls (Fig. 1i-j), consistent with
findings that 3-month old APPSw/0 mice show barely detect-
able Aβ deposition in the brain compared to 8.5-month old
mice, which begin depositing Aβ at that stage [55].
LRP1-dependent Aβ uptake by pericytes on mouse brain
slices
To confirm Aβ uptake by pericytes, we next conducted Aβ
uptake experiments on freshly isolated acute cortical slice
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cultures, as previously reported [48]. In this experiment,
the mouse brains slices were left to equilibrate in aCSF for
20 min at 37 °C with aeration, that was followed by
incubation with Cy3-Aβ42 (1 μM) for 30 min or 2 h. Con-
focal microscopy was performed to analyze Aβ internaliza-
tion by pericytes (Fig. 2a). We found that uptake of
Cy3-Aβ42 by pericytes was rapid and time-dependent.
Compared to 30 min, at 2 h the amount of internalized
Cy3-Aβ42 in CD13+ pericytes was further significantly
increased (Fig. 2b-c). In these studies, Aβ42 preparation
contained a mixture of Aβ42 monomers, dimers, trimers,
tetramers, and small molecular weight oligomers
(Additional file 1: Figure S2). Both low (Fig. 2b) and high
(Fig. 2d) magnification imaging analysis showed strong
Cy3-Aβ42 fluorescence signal in CD13+ pericytes and/or
PDGFRβ+ pericytes (Additional file 1: Figure S3A-B). In
addition to pericytes, Cy3-Aβ42 uptake was observed by
endothelial cells, astrocytes and microglia (Additional file 1:
Figure S3C-E). The intracellular Cy3-Aβ42 levels in peri-
cytes were significantly reduced in the presence of an
anti-LRP1-specific antibody [22, 29] and the receptor asso-
ciated protein (RAP) [52], an LRP1 antagonist which in-
hibits ligand binding to LRP1 (Fig. 2d), as shown by 17.1%
and 21.7% of the Cy3-Aβ42+ area occupying CD13+
Fig. 1 Aβ accumulation in brain pericytes in AD patients and 8.5-month-old APPSw/0 mice. a-f Representative confocal microscopy images
showing Aβ colocalization with CD13+ (a-b) and PDGFRβ+ (d-e) pericytes in brain cortical sections from AD patients compared to negligible
levels in age-matched controls, and quantification of Aβ + area in pericytes expressed as the percentage of Aβ + area occupying CD13+ (c) or
PDGFRβ+ (f) pericyte capillary profiles. N = 6 per group; mean ± s.d., p < 0.01 by Student’s t-test. Orthogonal views shown on the right in A, B, D
and E are from 10 μm Z-stacks. Scale bar, 25 μm. g-i Representative confocal microscopy images showing Aβ colocalization with CD13+ pericytes
(g) in brain sections from 8.5-month old APPSw/0 mice and age-matched littermate control, and quantification of Aβ + area within CD13+ pericyte
profiles in APPSw/0 mice and controls (h). N = 3 mice per group; mean ± SD, p < 0.001 by Student’s t-test. Orthogonal views from 10 μm Z-stacks.
Scale bar, 25 μm. i Representative images showing TUNEL staining (green) in CD13+ brain pericytes in 8.5-month old APPSw/0 mice. Lectin (blue),
labels brain endothelium. Aβ (white), shows perivascular and intracellular accumulation. Scale bar: 10 μm. Asterisk shows Aβ deposit; Arrowheads
show TUNEL+ CD13+ pericytes. j Quantification of TUNEL+ CD13+ pericytes in the cortex of 3- and 8.5-month old APPSw/0 mice compared to 8.5-
month old littermate controls. N = 3 mice per group; mean ± s.e.m.; p < 0.05 by Student’s t-test
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pericyte profiles, respectively, compared to > 80% in control
slices treated with vehicle or non-immune immunoglobulin
G (IgG) (Fig. 2d-e).
To further investigate the role of LRP1 in Cy3-Aβ42
uptake by pericytes, we generated conditional knockout
mice with LRP1 deficiency in pericytes (Lrp1lox/lox;
Cspg4-Cre) by crossing Lrp1lox/lox mice [44, 45] with
Cspg4-Cre mice [46] (Fig. 3a). As expected, CD13+ peri-
cytes on isolated brain microvessels from Lrp1lox/lox;
Cspg4-Cre mice did not show a detectable LRP1 immu-
noreactivity in contrast to pericytes from control
Lrp1lox/lox mice, whereas LRP1 remained expressed in
lectin+ endothelium in both Lrp1lox/lox; Cspg4-Cre and
Lrp1lox/lox microvessels (Fig. 3b), confirming selective de-
letion of LRP1 from brain capillary pericytes. Both,
Lrp1lox/lox and Lrp1lox/lox; Cspg4-Cre mice had compar-
able CD13+ pericyte coverage (Additional file 1: Figure
S4). Next, we studied Cy3-Aβ42 uptake on brain slices
from these mice, as described above. Two hours after in-
cubation, Cy3-Aβ42 uptake by CD13+ pericytes was re-
duced by > 80% in Lrp1 lox/lox; Cspg4-Cre mice compared
to control Lrp1 lox/lox mice (Fig. 3c-e). As expected, Aβ
uptake by other cell types shown collectively as CD13-
cells was not affected in this Lrp1 conditional knockout
model (Fig. 3f ). In summary, these data demonstrate
LRP1-depedent uptake of Aβ42 species by pericytes.
Fig. 2 LRP1-dependent Cy3-Aβ42 uptake by pericytes in mouse brain slices. a A diagram illustrating the experimental procedure in cultured
mouse brain slices used to determine Cy3-Aβ42 uptake by pericytes. Brain slices were first cultured in transwell inserts with oxygenated aCSF (see
method) for 4 h before adding Cy3-Aβ42 (1 μM). b-c Representative low-magnification images (b) and quantification (c) of cellular uptake of Cy3-
Aβ42 by CD13+ pericytes in brain slices at 30 min and 2 h after the addition of Cy3-Aβ42. Scale bar: 25 μm. d Representative high magnification
images showing Cy3-Aβ42 internalization by CD13-positive pericytes in brain slices in 2 h, in the presence of NI-IgG, anti-LRP1 or RAP. Scale bar:
20 μm. Orthogonal views on the right show Cy3-Aβ42 accumulation in CD13+ pericytes; scale bar: 5 μm. e Quantification of Cy3-Aβ42 uptake by
CD13+ pericytes in mouse brain slices with and without NI-IgG, anti-LRP1, and RAP. N = 4 independent cultures; mean ± s.e.m.; p < 0.05 by
One-way ANOVA followed by Bonferroni post-hoc test. Asterisks show colocalization of Cy3-Aβ42 and CD13 signals in (b) and (d)
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LRP1/apoE-dependent clearance of aggregated Cy3-Aβ42
by mouse brain capillary pericytes
To determine whether pericytes can clear aggregated
Aβ, we used a slightly modified Aβ clearance model with
pericytes seeded on multi-spot glass slides pre-coated
with aggregated Cy3-Aβ42, as we reported previously in
studies with primary VSMCs [29] (Fig. 4a). Five days
after culture, the majority of Aβ42 aggregates (> 70%)
were removed from the multi-spot surface by pericytes
in the presence of vehicle, control non-immune IgG or
scrambled short interfering si.Control (Fig. 4b-c), when
compared to cell-free control (Fig. 4a). In contrast, only
22.8%, 27.3% and 12.9% of Cy3-Aβ42 was cleared in the
presence of anti-LRP1 [22, 29], RAP [52] and si.Lrp1
(Fig. 4c), respectively. In silencing experiment, si.Lrp1 ef-
ficiently downregulated LRP1 in pericytes by ~ 90%
when compared to si.Control (Additional file 1: Figure
S5A). We also found a time-dependent increase in cell
death of pericytes cultured on Aβ pre-coated slides,
from 8.2% at 3 DIV to 18.7% at 5 DIV, whereas inhibit-
ing LRP1 by an anti-LRP1 antibody or LRP1 silencing
(si.Lrp1), not only significantly reduced Aβ uptake, but
Fig. 3 LRP1 genetic deletion from pericytes inhibits Cy3-Aβ42 uptake by pericytes in mouse brain slices. a Diagram illustrating generation of Lrp1lox/lox;
Cspg4-Cre mice by crossing Lrp1lox/lox mice with Cspg4-Cre mice. b Representative high magnification images showing LRP1 expression in CD13+
pericytes on isolated murine brain capillaries from control Lrp1lox/lox mice, but not Lrp1lox/lox; Cspg4-Cre mice with LRP1 deletion from pericytes. Asterisks
show LRP1 immunostaining in CD13+ pericytes in control Lrp1lox/lox mice; arrow shows loss of LRP1 immunoreactivity in Lrp1lox/lox; Cspg4-Cre mice.
Scale bar: 5 μm. c Representative images showing Cy3-Aβ42 internalization by CD13+ pericytes in brain slices from control Lrp1lox/lox mice, and a
substantial loss of Cy3-Aβ42 uptake by pericytes in Lrp1lox/lox; Cspg4-Cre mice. Asterisks show colocalization between Cy3-Aβ42 and CD13 signals. Scale
bar: 25 μm. d High magnification images showing greatly reduced Cy3-Aβ42 internalization by a CD13+ pericyte on brain slices from Lrp1lox/lox; Cspg4-
Cre mice, in contrast to Aβ uptake by lectin-positive endothelial cells. Arrow points to pericyte lacking Cy3-Aβ42 signal. Scale bar: 5 μm. e, f
Quantification of Cy3-Aβ42 cellular uptake by CD13+ pericytes (e) compared to all other CD13- (negative) brain cells (f) in brain slices from control Lrp1
lox/lox and Lrp1 lox/lox; Cspg4-Cre mice. N = 3 mice per group; mean ± s.e.m.; NS, not significant, p < 0.05 by Student’s t-test
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also diminished pericyte cell death by approximately 3
and 4-fold at 3 and 5 DIV, respectively (Fig. 4d), suggest-
ing that reducing Aβ uptake decreases Aβ toxicity con-
sistent with previous studies with soluble Aβ [37] or
Dutch Aβ peptides [54].
To check whether apoE is required for LRP1-mediated
clearance of Aβ aggregates, we studied clearance by peri-
cytes in the presence of an apoE specific blocking antibody
compared to non-immune IgG, and after silencing mouse
apoE (si.Apoe) compared to scrambled si.Control (Additional
file 1: Figure S5B; Fig. 5a). After 5 days, we found substan-
tially reduced Aβ clearance with either pharmacologic or
genetic inhibition of murine apoE in pericytes as illustrated
by representative confocal microscopy images (Fig. 5a),
quantification of time-dependent Cy3-Aβ42 clearance by
mouse pericytes cultured for 1, 3 and 5 days after silencing
mouse endogenous apoE (si.Apoe) compared to si.Control
(Fig. 5b), and quantification analysis of Cy3-Aβ42 relative
signal intensity on multi-spot slides after 5 days of culture
with pericytes under different experimental conditions (Fig.
5c). These data suggest that pericyte-derived apoE is
required for clearance of Aβ aggregates by cultured peri-
cytes, which we show is mediated by LRP1, an apoE recep-
tor (see Fig. 2d-e; Fig. 3c-e and Fig. 4b-c). Besides the
self-autonomous effect of apoE in regulating clearance of
Aβ aggregates by pericytes (Fig. 5a-c), to mimic in vivo situ-
ation we next studied the non-autonomous effects of
astrocyte-derived apoE by adding lipidated human apoE3 or
apoE4 particles prepared from immortalized astrocytes, as
previously described [53]. Previous work has shown that
astrocyte-derived apoE provides a major source of apoE in
the brain in vivo and signals pericytes via LRP1, but not
LRP2, very low density lipoprotein receptor (VLDLR), low
density lipoprotein receptor (LDLR) or apoER2 [49]. The
effects of apoE3 and apoE4 on Aβ clearance by pericytes
was studied after silencing mouse apoE (si.Apoe). ApoE3,
but not apoE4, almost completely reversed Aβ clearance by
pericytes with inhibited mouse apoE (Fig. 5a-c), suggesting
that astrocyte-derived apoE exerts a non-autonomous
isoform-specific effect on Aβ clearance by pericytes. To
additionally confirm that apoE3 effect on pericytes requires
LRP1 as previously shown [49], we performed the same
Fig. 4 LRP1 mediates clearance of aggregated Cy3-Aβ42 by mouse pericytes. a-b Multiphoton/confocal laser scanning microscopy of multi-spot glass
slides coated with Cy3-Aβ42 without cells (a), and with primary mouse brain pericytes cultured for 5 days in the presence of NI-IgG or anti-LRP1, after
si.Lrp1 silencing compared to scrambled si.Control, and with RAP or vehicle (b). Scale bar, 50 μm. c Quantification of Cy3-Aβ42 relative signal intensity
on multi-spot slides after 5 days without cells (open bar on the left) and with pericytes in the presence of vehicle (control), NI-IgG and anti-LRP1, after
silencing with scrambled si.Control or si.Lrp1, and in the presence of RAP. N = 4 independent cultures (biological replicates, see Methods); mean ±
s.e.m.; p < 0.05 by One-way ANOVA followed by Bonferroni post-hoc test. d Quantification of TUNEL+ pericyte cell death at 3 and 7 days after seeding
on multi-spot glass slides coated with Cy3-Aβ42 in the presence and absence of NI-IgG and anti-LRP1, and after si.Lrp1 silencing or si.Ctrl as in (b). N =
3 independent cultures per group; mean ± s.e.m.; p < 0.05 by One-way ANOVA followed by Bonferroni post-hoc test
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experiment in the presence of an anti-LRP1 antibody. As ex-
pected, this experiment showed that anti-LRP1 inhibits
apoE3’s ability to reverse the Aβ clearing capability of mouse
pericytes with silenced mouse apoE (si.Apoe) (Fig. 5a, c).
Discussion
Our data show that BBB-associated pericytes accumulate
an abundance of Aβ on brain capillaries in AD patients
and APPSw/0 mice. We also show that pericytes play a
major role in clearance of different Aβ42 species including
a mixture of monomers and small molecular weight oligo-
mers, which is mediated via LRP1, similar as previously
shown for Aβ40 [37]. This has been demonstrated by
pharmacologic inhibition of LRP1 by an anti-LRP1
antibody [22, 29] and RAP [52], genetic Lrp1 knockdown
with short interfering RNA (si.Lrp1) and deletion of LRP1
from pericytes in Lrplox/lox;Cspg4-Cre mice compared to
Lrplox/lox controls. Moreover, we show that pericytes effi-
ciently clear Aβ42 aggregates by an LRP1/apoE
isoform-specific mechanism. This has been demonstrated
by silencing mouse Apoe (si.Apoe) in pericytes in the ab-
sence and presence of human astrocyte-derived lipidated
apoE3 or apoE4, which revealed that apoE3, but not
apoE4, mediates LRP1-dependent clearance of Cy3-Aβ42
aggregates. Overall, these data point to Aβ clearance on
pericytes as a possible contributory factor in the patho-
genesis of AD and accumulation of Aβ in the brain and
around brain capillaries causing capillary CAA as seen in
Fig. 5 Apolipoprotein E-dependent and isoform-specific effect on LRP1-mediated clearance of aggregated Cy3-Aβ42 by mouse pericytes. a
Multiphoton/confocal laser scanning microscopy of multi-spot glass slides coated with Cy3-Aβ42 with primary mouse brain pericytes cultured for
5 days in the presence of mouse apoE-specific blocking antibody (anti-apoE), after silencing mouse endogenous apoE (si.Apoe) compared to
scrambled si.Control, and after silencing mouse apoE (si.Apoe) in the presence of astrocyte-derived lipidated human apoE3 or apoE4 (40 nM) with
and without anti-LRP1 antibody. Scale bar, 50 μm. b Time-dependent Cy3-Aβ42 clearance by mouse pericytes cultured for 1, 3 and 5 days after
silencing mouse endogenous apoE (si.Apoe) compared to si.Control, and in the presence of human apoE3 or apoE4. Dashed line indicates Cy3-
Aβ42 signal in the absence of cells (control without cells). c Quantification analysis of Cy3-Aβ42 relative signal intensity on multi-spot slides after
5 days of culture with pericytes under different experimental conditions as indicated. Gray bar shows Cy3-Aβ42 signal in the absence of cells
(control without cells). N = 3 independent cultures; mean ± s.e.m.; p < 0.05 by one-way ANOVA followed by Bonferroni post-hoc test
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AD [8]. The data also suggest that LRP1/apoE interaction
on pericytes should be explored further as a potential
therapeutic approach for controlling Aβ clearance in AD.
Accumulation of Aβ in pericytes in AD and APP mouse
brain capillaries likely reflects Aβ overload that exceeds
pericytes clearance capability resulting in intracellular trap-
ping of Aβ. This in turn may set a stage for the formation
of amyloid deposits around brain capillaries and within the
basement membrane between pericytes and endothelial
cells, as shown in AD [7, 8] and APP models [21]. Consist-
ent with these findings we also observed accumulation of
Aβ in the brain endothelium in both AD and APPSw/0 mice
likely reflecting excess Aβ that has not been cleared via
transport across the BBB [27]. Collectively, these data sug-
gest that not only previously shown faulty clearance of Aβ
on VSMCs contributes to CAA and Aβ pathology [29, 30],
but also impaired clearance on pericytes may contribute to
development of capillary CAA [8, 21] and retention of Aβ
in the brain. This might be particularly important at disease
stages when other clearance mechanisms including Aβ
drainage by the perivascular route and/or the meningeal
lymphatics become deficient, as recently shown in APP
mouse models [16, 17].
Pericyte degeneration and loss have been reported in
AD patients [47, 56–59] and APP mice [37, 60]. Consist-
ent with previous findings demonstrating that excess Aβ
in pericytes can trigger cell death in human [54] and
mouse [37] pericytes, we also found that pericytes in
APPSw/0 mice die at the time of Aβ deposition in the
brain and its accumulation in pericytes. Pericyte cell
death, in turn, can exacerbate progression of AD path-
ology, as shown in APPSw/0; Pdgfrb+/− mice with acceler-
ated pericyte loss [37]. Similar as shown in human
pericytes [54], we also found that LRP1 mediates both
Aβ internalization and cell death of mouse pericytes, as
illustrated by diminished Aβ uptake and reduced cell
death in the presence of LRP1 inhibition by either an
anti-LRP1 antibody and/or Lrp1 silencing. Consistent
with the present findings, previous studies by Verbeek
and colleagues [54, 61–63] suggested that Aβ effects on
pericytes are modulated by apoE isoforms. In brief, they
showed that human pericytes from apoE4 carriers com-
pared to apoE3 carriers secrete less apoE in the culture
media resulting in increased accumulation of Dutch Aβ
peptide on the cell surface and greater rate of cell death
induced by Aβ [63].
Interestingly, loss of pericytes in human AD is
significantly higher in apoE4 carriers compared to apoE3
carriers, which is associated with greater degree of BBB
breakdown [56, 64], and increased risk for CAA, as
shown both in human apoE4 compared to apoE3
carriers [65–69], and APP mouse models on apoE4
compared to apoE3 background [66, 70]. These findings
are consistent with the present data showing that human
astrocyte-derived apoE4, in contrast to apoE3, cannot
reverse LRP-1-mediated Aβ clearance by mouse
pericytes with silenced mouse endogenous apoE, and
previous findings demonstrating that apoE4 compared
to apoE3 poorly binds to LRP1, which leads from on one
hand to BBB breakdown by activating BBB-degrading
cyclophilin-A-matrix metallopropteinase-9 pathway in
pericytes [49], and from the other, diminished clearance
of Aβ across the BBB [39].
Finally, the present findings showing that pericytes ac-
tively contribute to Aβ removal at the BBB via
LRP1-mediated apoE isoform-dependent clearance on
brain capillaries should encourage future studies di-
rected at exploring possible therapeutic potential of this
pathway to control CAA and Aβ pathology in AD. For
example, pharmacologic or genetic strategies that can in-
crease activity of LRP1/apoE clearance system in peri-
cytes and at the BBB might diminish CAA and Aβ
accumulation in apoE3 carriers, but may not work as
well in apoE4 carriers. On the other hand, recent cell
therapy studies have shown that mouse mesodermal
pericytes can improve cerebral blood flow and reduce
Aβ pathology when injected into the brain of APP mice
[38]. Based on the present findings, this therapeutic ef-
fect likely depends on mouse endogenous apoE. When
translating this approach to humans, based on the
present findings one can envisage using iPSC-derived
pericytes from apoE3 carriers as a straight Aβ lowering
cell clearance therapy, whereas in case of apoE4 carriers,
CRISPER/Cas9 approach could be used to generate
apoE3-secreting iPSC-derived pericytes with enhanced
Aβ clearance properties.
Conclusions
In conclusion, our findings show that BBB-associated
pericytes clear Aβ aggregates via an LRP1-dependent
apoE isoform-specific mechanism with apoE4 disrupting
Aβ clearance compared to apoE3. Overall, the present
data support that the LRP1/apoE pathway in pericytes
has a potential to be explored as a therapeutic target for
controlling Aβ clearance and levels in AD.
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